| 查看: 355 | 回复: 1 | |||
johncena木虫 (小有名气)
|
[求助]
急求usp35版药典中Rivastigmine Tartrate 的质量标准
|
| 如题,哪位虫友有pdf的话麻烦发我一份,在目录上查询应该是在p4580和p4581,谢谢! |
» 猜你喜欢
材料求调剂 一志愿哈工大总分298分,前三科223分
已经有4人回复
086502化学工程342求调剂
已经有3人回复
求调剂
已经有9人回复
352分 化工与材料
已经有5人回复
085602 化工专硕 338分 求调剂
已经有10人回复
0856材料化工调剂 总分330
已经有10人回复
330一志愿中国海洋大学 化学工程 085602 有读博意愿 求调剂
已经有4人回复
一志愿哈尔滨工业大学材料与化工方向336分
已经有6人回复
材料求调剂一志愿哈工大324
已经有6人回复
085600 286分 材料求调剂
已经有4人回复
» 本主题相关价值贴推荐,对您同样有帮助:
仿制药质量标准的制定
已经有12人回复
求USP35中Eprinomectin的质量标准
已经有3人回复
求助关于质量标准有关物质问题
已经有15人回复
头孢呋辛酯颗粒现行的质量标准是什么
已经有7人回复
泡泡-211
至尊木虫 (知名作家)
- PhEPI: 1
- 应助: 101 (高中生)
- 金币: 12710.8
- 红花: 8
- 沙发: 35
- 帖子: 7496
- 在线: 1516小时
- 虫号: 293006
- 注册: 2006-11-04
- 性别: GG
- 专业: 药剂学
【答案】应助回帖
★ ★ ★
感谢参与,应助指数 +1
johncena: 金币+3, ★★★★★最佳答案, 感谢你的帮助! 2012-09-02 13:24:28
感谢参与,应助指数 +1
johncena: 金币+3, ★★★★★最佳答案, 感谢你的帮助! 2012-09-02 13:24:28
|
Rivastigmine Tartrate C14H22N2O2 · C4H6O6 400.42 Ethylmethylcarbamic acid, 3-[(S)-1-(dimethylamino)ethyl]phenyl ester, (2R ,3R )-2,3-dihydroxybutanedioate; (S)-3-[1-(Dimethylamino)ethyl]phenyl ethylmethylcarbamate, hydrogen tartrate [129101-54-8]. Rivastigmine 250.34 [123441-03-2]. DEFINITION Rivastigmine Tartrate contains NLT 98.0% and NMT 102.0% of the labeled amount of C14H22N2O2 · C4H6O6 , calculated on the anhydrous basis. IDENTIFICATION • A. Infrared Absorption 197K • B. The retention time of the major peak of the Sample solution corresponds to that of the System suitability solution, as obtained in the test for Organic Impurities, Procedure 2: Enantiomeric Purity. ASSAY • Procedure Buffer: 8.6 mg/mL of monobasic ammonium phosphate. Adjust with ammonia solution to a pH of 7.0. Mobile phase: Methanol, acetonitrile, and Buffer (15:15:70) System suitability solution: 0.05 mg/mL each of USP Rivastigmine Related Compound A RS and USP Rivastigmine Related Compound B RS in Mobile phase Standard solution: 0.2 mg/mL of USP Rivastigmine Tartrate RS in Mobile phase Sample solution: 0.2 mg/mL of Rivastigmine Tartrate in Mobile phase Chromatographic system (See Chromatography 621 , System Suitability.) Mode: LC Detector: UV 215 nm Column: 4.6-mm × 25-cm; 5-μm packing L7 Flow rate: 1.2 mL/min Injection size: 20 μL [Note— The flow rate may be adjusted to 1.5 mL/min, if needed, to achieve a recommended retention time of rivastigmine at about 10 min. ] System suitability Samples: System suitability solution and Standard solution Suitability requirements Resolution: NLT 1.5 between rivastigmine related compound A and rivastigmine related compound B, System suitability solution Column efficiency: NLT 5000 theoretical plates, Standard solution Tailing factor: NMT 3.0, Standard solution Relative standard deviation: NMT 2.0%, Standard solution Analysis Samples: Standard solution and Sample solution Calculate the percentage of C14H22N2O2 · C4H6O6 in the portion of Rivastigmine Tartrate taken: Result = (rU /rS ) × (CS /CU ) × 100 rU = = peak response from the Sample solution rS = = peak response from the Standard solution CS = = concentration of the Standard solution (mg/mL) CU = = concentration of the Sample solution (mg/mL) Acceptance criteria: 98.0%–102.0% on the anhydrous basis IMPURITIES Inorganic Impurities • Residue on Ignition 281 : NMT 0.1% • Heavy Metals, Method II 231 : NMT 20 ppm Organic Impurities • Procedure 1 Mobile phase and System suitability solution: Proceed as directed in the Assay. Standard solution: 1.0 μg/mL of USP Rivastigmine Tartrate RS in Mobile phase Sample solution: 1.0 mg/mL of Rivastigmine Tartrate in Mobile phase Chromatographic system: Proceed as directed in the Assay. (See Chromatography 621 , System Suitability.) System suitability Samples: System suitability solution and Standard solution Suitability requirements Resolution: NLT 1.5 between rivastigmine related compound A and rivastigmine related compound B, System suitability solution Relative standard deviation: NMT 10%, Standard solution Analysis [Note— The run time is 8 times the retention time of the rivastigmine peak. ] Samples: Standard solution and Sample solution Calculate the percentage of any individual impurity in the portion of Rivastigmine Tartrate taken: Result = (rU /rS ) × (CS /CU ) × (1/F) × 100 rU = = peak response for each impurity from the Sample solution rS = = peak response from the Standard solution CS = = concentration of USP Rivastigmine Tartrate RS in the Standard solution (mg/mL) CU = = concentration of Rivastigmine Tartrate in the Sample solution (mg/mL) F = = relative response factor (see Impurity Table 1) Acceptance criteria Individual impurities: See Impurity Table 1. Total impurities: NMT 0.5% Impurity Table 1 Name Relative Retention Time Relative Response Factor Acceptance Criteria, NMT (%) Tartrate 0.18 — Disregard Phenol impuritya 0.28 1.6 0.3 DPTTAb 0.46 0.83 0.15 Nor impurityc 0.57 1.2 0.15 Rivastigmine 1.0 1.0 — Carbamate impurityd 4.1 1.3 0.15 Ether impuritye 6.5 1.4 0.15 Any other impurity — 1.0 0.1 a (S)-3-[1-(Dimethylamino)ethyl]phenol. b (+)-Di-(p-toluoyl)-d-tartaric acid (rivastigmine related compound A). c (S)-3-[1-(Dimethylamino)ethyl]phenyl dimethylcarbamate (rivastigmine related compound B). d 3-Nitrophenyl ethyl(methyl)carbamate. e (S)-N,N-Dimethyl-1-[3-(4-nitrophenoxy)phenyl]ethanamine. • Procedure 2: Enantiomeric Purity Buffer: Transfer 1.78 g of dibasic sodium phosphate dihydrate and 1.38 g of monobasic sodium phosphate into a 1000-mL volumetric flask. Dissolve in and dilute with water to volume. Adjust with phosphoric acid to a pH of 6.0. Mobile phase: Transfer 20 mL of acetonitrile and 205 μL of N,N-dimethyloctylamine to a 1000-mL volumetric flask, and dilute with Buffer to volume. Standard solution: 0.1 μg/mL of USP Rivastigmine Tartrate R-Isomer RS in Mobile phase Sensitivity solution: 0.05 μg/mL of USP Rivastigmine Tartrate R-Isomer RS in Mobile phase, Standard solution System suitability solution: 100 μg/mL of USP Rivastigmine Tartrate RS and 0.1 μg/mL of USP Rivastigmine Tartrate R-Isomer RS in Mobile phase Sample solution: 100 μg/mL of Rivastigmine Tartrate in Mobile phase Chromatographic system (See Chromatography 621 , System Suitability.) Mode: LC Detector: UV 200 nm Column: 4.0-mm × 10-cm; packing L41 Flow rate: 0.5 mL/min Injection size: 20 μL System suitability Samples: Standard solution, Sensitivity solution, and System suitability solution Suitability requirements Resolution: NLT 0.8 between the enantiomer peaks, System suitability solution [Note— The elution order is the R-enantiomer, followed by the rivastigmine peak, which is the S-enantiomer. ] Signal-to-noise ratio: NLT 10, Sensitivity solution Relative standard deviation: NMT 10%, Standard solution Analysis Samples: Standard solution and Sample solution Calculate the percentage of the R-enantiomer in the portion of Rivastigmine Tartrate taken: Result = (rU /rS ) × (CS /CU ) × 100 rU = = peak response of R-enantiomer from the Sample solution rS = = peak response of R-enantiomer from the Standard solution CS = = concentration of R-enantiomer in the Standard solution (μg/mL) CU = = concentration of Rivastigmine Tartrate in the Sample solution (μg/mL) Acceptance criteria: NMT 0.3% of the R-enantiomer SPECIFIC TESTS • Water Determination, Method Ia 921 : NMT 0.5% ADDITIONAL REQUIREMENTS • Packaging and Storage: Preserve in tight containers, and store at room temperature. • USP Reference Standards 11 USP Rivastigmine Tartrate RS USP Rivastigmine Related Compound A RS Di-p-toluoyl-d-(+)-tartaric acid monohydrate. C20H20O9 404.37 USP Rivastigmine Related Compound B RS N,N-Dimethylcarbamic acid-3-[1-(dimethylamino)ethyl]phenyl ester. C13H20N2O2 236.32 USP Rivastigmine Tartrate R-Isomer RS |

2楼2012-08-31 17:11:47














回复此楼